170 related articles for article (PubMed ID: 35936669)
1. Carbon Ion Radiotherapy Induce Metabolic Inhibition After Functional Imaging-Guided Simultaneous Integrated Boost for Prostate Cancer.
Pei Y; Ning R; Hu W; Li P; Zhang Z; Deng Y; Hong Z; Sun Y; Guo X; Zhang Q
Front Oncol; 2022; 12():845583. PubMed ID: 35936669
[TBL] [Abstract][Full Text] [Related]
2. Carbon Ion Radiotherapy Evokes a Metabolic Reprogramming and Individualized Response in Prostate Cancer.
Ning R; Pei Y; Li P; Hu W; Deng Y; Hong Z; Sun Y; Zhang Q; Guo X
Front Public Health; 2021; 9():777160. PubMed ID: 34950631
[No Abstract] [Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. The metabolic repression effect of carbon-ion radiotherapy in synchronous hormone-sensitive oligometastatic prostate cancer.
Zhang Z; Pei Y; Hu W; Xue Y; Ning R; Guo X; Sun Y; Zhang Q
Front Endocrinol (Lausanne); 2023; 14():1291653. PubMed ID: 38027094
[TBL] [Abstract][Full Text] [Related]
5. Functional imaging-guided carbon ion irradiation with simultaneous integrated boost for localized prostate cancer: study protocol for a phase II randomized controlled clinical trial.
Hu W; Li P; Hong Z; Guo X; Pei Y; Zhang Z; Zhang Q
Trials; 2022 Nov; 23(1):934. PubMed ID: 36348363
[TBL] [Abstract][Full Text] [Related]
6. Up modulation of dose-averaged linear energy transfer by simultaneous integrated boost in carbon-ion radiotherapy for pancreatic carcinoma.
Wang W; Sun J; Zhao J; Cheng J; Jiang GL; Wang Z
J Appl Clin Med Phys; 2024 Jan; ():e14279. PubMed ID: 38259194
[TBL] [Abstract][Full Text] [Related]
7. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
8. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
9.
Mastella E; Molinelli S; Magro G; Russo S; Bonora M; Ronchi S; Ingargiola R; Jensen AD; Ciocca M; Vischioni B; Orlandi E
Front Oncol; 2021; 11():772580. PubMed ID: 34966678
[TBL] [Abstract][Full Text] [Related]
10. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
12. Biological and clinical significance of radiomics features obtained from magnetic resonance imaging preceding pre-carbon ion radiotherapy in prostate cancer based on radiometabolomics.
Zhang G; Zhang Z; Pei Y; Hu W; Xue Y; Ning R; Guo X; Sun Y; Zhang Q
Front Endocrinol (Lausanne); 2023; 14():1272806. PubMed ID: 38027108
[TBL] [Abstract][Full Text] [Related]
13. Intraindividual comparison between
Spohn S; Jaegle C; Fassbender TF; Sprave T; Gkika E; Nicolay NH; Bock M; Ruf J; Benndorf M; Gratzke C; Grosu AL; Zamboglou C
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2796-2803. PubMed ID: 32342192
[TBL] [Abstract][Full Text] [Related]
14. [
Bettermann AS; Zamboglou C; Kiefer S; Jilg CA; Spohn S; Kranz-Rudolph J; Fassbender TF; Bronsert P; Nicolay NH; Gratzke C; Bock M; Ruf J; Benndorf M; Grosu AL
Radiother Oncol; 2019 Dec; 141():214-219. PubMed ID: 31431366
[TBL] [Abstract][Full Text] [Related]
15. Carbon ion radiotherapy for prostate cancer with bladder invasion.
Miyasaka Y; Kawamura H; Sato H; Kubo N; Mizukami T; Matsui H; Miyazawa Y; Ito K; Nakano T; Suzuki K; Ohno T
BMC Urol; 2021 Aug; 21(1):106. PubMed ID: 34362355
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts.
Goodman CD; Fakir H; Pautler S; Chin J; Bauman GS
Adv Radiat Oncol; 2020; 5(2):212-220. PubMed ID: 32280821
[TBL] [Abstract][Full Text] [Related]
17. Effect of androgen deprivation therapy on intraprostatic tumour volume identified on
Chan J; Carver A; Brunt JN; Vinjamuri S; Syndikus I
Br J Radiol; 2017 Mar; 90(1071):20160818. PubMed ID: 27993093
[TBL] [Abstract][Full Text] [Related]
18. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
19. Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
Kasuya G; Ishikawa H; Tsuji H; Nomiya T; Makishima H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Haruyama Y; Kobashi G; Tsujii H;
Cancer; 2016 Oct; 122(20):3225-3231. PubMed ID: 27351298
[TBL] [Abstract][Full Text] [Related]
20. Comparison of
Zhou C; Tang Y; Deng Z; Yang J; Zhou M; Wang L; Hu S
EJNMMI Res; 2022 Feb; 12(1):10. PubMed ID: 35147810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
